Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 2.62M | 3.10M | 2.85M | 718.67K | 275.25K | 442.10K |
Gross Profit | 2.62M | 3.10M | 2.74M | 698.06K | 275.25K | 434.37K |
EBITDA | -6.91M | -5.67M | -7.72M | -4.06M | -1.80M | -1.03M |
Net Income | -7.99M | -6.40M | -5.06M | -3.39M | -1.52M | -696.36K |
Balance Sheet | ||||||
Total Assets | 11.39M | 12.27M | 8.37M | 10.59M | 4.13M | 819.55K |
Cash, Cash Equivalents and Short-Term Investments | 7.01M | 6.47M | 3.17M | 9.57M | 3.41M | 416.23K |
Total Debt | 1.30M | 1.52M | 1.06M | 0.00 | 0.00 | 300.00K |
Total Liabilities | 2.12M | 3.68M | 3.16M | 950.42K | 525.60K | 380.64K |
Stockholders Equity | 9.27M | 8.59M | 5.21M | 9.64M | 3.61M | 438.92K |
Cash Flow | ||||||
Free Cash Flow | -8.07M | -5.67M | -6.41M | -7.25M | -1.21M | -665.46K |
Operating Cash Flow | -6.31M | -4.52M | -6.05M | -3.22M | -1.21M | -661.65K |
Investing Cash Flow | -2.79M | -1.15M | 3.64M | -4.03M | -3.85K | -3.81K |
Financing Cash Flow | 16.18M | 8.97M | 13.24K | 9.41M | 4.20M | 805.04K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $7.50B | 0.32 | -61.87% | 2.27% | 17.10% | 1.59% | |
45 Neutral | AU$20.96M | ― | -51.49% | ― | 80.84% | 57.59% | |
45 Neutral | AU$41.30M | ― | -39.07% | ― | 26.07% | 0.85% | |
40 Neutral | AU$2.42M | ― | ― | 55.07% | 88.20% | ||
40 Neutral | AU$24.52M | ― | -104.23% | ― | ― | -17.26% | |
38 Underperform | AU$15.68M | ― | -71.10% | ― | ― | 76.17% | |
AU$1.48M | ― | ― | ― | ― |
BCAL Diagnostics Limited has announced a strategic partnership with Cancer Care Associates to accelerate the adoption of their non-invasive breast cancer diagnostic test, BREASTEST plus™. This partnership is a significant commercial milestone for BCAL, providing a pathway to market adoption and patient access through a leading oncology network in Australia. The collaboration is expected to generate revenue starting in FY2026 and strengthen BCAL’s commercial rollout strategy, potentially leading to broader national and international partnerships. The integration of BREASTEST plus™ into Cancer Care Associates’ offerings will support uptake in various settings and enhance BCAL’s data collection efforts, aiding discussions around reimbursement and regulatory approvals.
BCAL Diagnostics Limited has announced the expansion of its BREASTEST plus blood test to three additional specialist breast clinics in Sydney and Melbourne, starting mid-May 2025. This expansion aligns with BCAL’s national rollout strategy to improve early breast cancer detection in women with high breast density, a group where traditional mammography often faces challenges. The move is a significant milestone in BCAL’s efforts to provide more women with access to this breakthrough diagnostic tool, enhancing early and accurate diagnosis and potentially improving health outcomes.
BCAL Diagnostics Limited has launched its first-in-class blood test, BREASTEST plus, which achieved its first revenues in March 2025. This launch represents a significant milestone in breast cancer diagnostics, particularly for women with dense breasts where traditional imaging is less effective. The company is expanding its market access and clinician engagement strategies in Australia, with plans for a national rollout, while also laying the groundwork for US market entry. BCAL continues to strengthen its patent portfolio and maintain a solid financial position with a cash balance of $5 million, focusing on efficient resource deployment to achieve its strategic objectives.